Trial Profile
UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Melphalan (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 18 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 18 Aug 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 01 Dec 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.